Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

BACKGROUND: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. METHODS: We administered lambrolizuma...

詳細記述

保存先:
書誌詳細
主要な著者: Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D., Hersey, Peter, Joseph, Richard W., Weber, Jeffrey S., Dronca, Roxana, Gangadhar, Tara C., Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M., Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C., Chmielowski, Bartosz, Ebbinghaus, Scot W., Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni
フォーマット: Artigo
言語:Inglês
出版事項: 2013
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126516/
https://ncbi.nlm.nih.gov/pubmed/23724846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1305133
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料